What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2025-03-05 compared with 2024-03-13 · 29 added, 17 removed, 1 unchanged (98% of the section changed)

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

common stock is traded on the Nasdaq Capital Market under the symbol “ TARA ”.

of Our common stock

As of March 8,

2024, there were 11,433,837 shares of common stock outstanding held by approximately 17 stockholders of record.

The actual number of

stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, whose shares are

held in street name by brokers and other nominees.

have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in

the foreseeable future.

Payment of future dividends, if any, on our common stock will be at the discretion of our Board of Directors

after taking into account various factors, including our financial condition, operating results, anticipated cash needs, and plans for

Authorized for Issuance under Equity Compensation Plans

Item 12 of Part III of this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity

Market for Registrant’s Common Equity, Related Stockholder

Matters and Issuer Purchases of Equity Securities.

Our common stock is traded

on the Nasdaq Capital Market under the symbol “ TARA ”.

Holders of Our common stock

As of February 28, 2025, there were 36,767,465 shares of common stock outstanding

held by approximately 26 stockholders of record.

The actual number of stockholders is greater than this number of record holders, and

includes stockholders who are beneficial owners, whose shares are held in street name by brokers and other nominees.

Dividend Policy

We have never declared or

paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future.

Payment of future dividends, if any, on our common stock will be at the discretion of our Board of Directors after taking into account

various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion.

Securities Authorized for Issuance under Equity

Compensation Plans

Sales of Unregistered Securities

than as previously disclosed in our past Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, we did not have any sales of

unregistered securities for the period covered by this Annual Report on Form 10-K.

See Item 12 of Part III of

this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity compensation plans.

Recent Sales of Unregistered Securities

Common Warrant Exercises

On December 12, 2024, 725,000 of the common warrants issued in the

Company’s April 2024 private placement were exercised by an investor, at the exercise price of $5.25 per share, resulting in the

issuance of 725,000 shares of the Company’s common stock.

The securities sold in the April 2024 private placement were issued in

reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.

The aggregate gross proceeds

from the common warrant exercise was approximately $3.8 million.

The Company intends to use the proceeds for general corporate and working

capital purposes, including funding clinical trials.

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity